

4 AUGUST 2025

## PACIFIC EDGE SPP CLOSES; \$20.7 MILLION OF TOTAL NEW EQUITY PLEDGED

**DUNEDIN, New Zealand** – On 13 May 2025, cancer diagnostics company Pacific Edge Limited (“Pacific Edge”, the “Company”) (NZX, ASX: PEB) announced a \$20.0 million capital raise comprising a \$15.0 million placement and a \$5.0 million Share Purchase Plan (“SPP”).

The SPP closed on 31 July 2025, with subscriptions for ~\$4.7 million of new ordinary shares. The Directors have resolved to accept all eligible SPP applications in full.

The proceeds from the SPP, combined with an associated ~\$16.1 million Placement that preceded it, brings the new equity committed to the company to \$20.7 million in aggregate. This is greater than the \$20.0 million initially sought as the Placement was upsized after Directors resolved to accept oversubscriptions.

The Placement is conditional on shareholder approval, which is to be sought at the Annual Shareholders’ Meeting on 6 August 2025. The issue of shares under the SPP is conditional on the Placement becoming unconditional.

Subject to these conditions being met, the 207,350,411 new shares will be issued at \$0.10 per share. All shares issued as part of the Placement and the SPP are expected to be allotted to participants on 13 August 2025 and will rank equally with all ordinary shares on issue on that date.

### KEY DATES OF THE SPP\*

DATE	EVENT	DESCRIPTION
6 August 2025	Annual Shareholders’ Meeting	Shareholders’ meeting to, amongst other things, approve the Placement.
13 August 2025	Allotment Date and commencement of trading on NZX	Shares are allotted under the Placement and the SPP. Trading of the Shares is expected to commence on the NZX Main Board on the Allotment Date and on ASX on the business day following the Allotment Date.
13 August 2025	Holding Statements	Holding Statements are sent to Applicants who are allotted Shares under the SPP.

\* Subject to the NZX and ASX Listing Rules and applicable laws, Pacific Edge reserves the right to alter any dates for the SPP.

*Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.*

For more information:

**Investors:**

Dr Peter Meintjes  
Chief Executive  
Pacific Edge  
P: 022 032 1263

**Media:**

Richard Inder  
The Project  
P: +64 21 645 643

## OVERVIEW

**Pacific Edge:** [www.pacifiedgedx.com](http://www.pacifiedgedx.com)

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

**Cxbladder:** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.